Early Insight on Macular Degeneration. The AdaptDx.
MacuLogix is on a mission to eliminate blindness caused by AMD through earlier diagnosis and treatment. Our AdaptDx measures dark adaptation – the earliest biomarker for AMD – and is the only functional test to enable eye care professionals to screen for and accurately diagnose AMD, at least three years before structural changes are visible in the retina. Dark adaptation testing with the AdaptDx offers an objective and highly accurate assessment measurement, is easy to interpret, and is patient and technician friendly. It is reimbursable under CPT code 92284 (national average $64.08).
Brands: AdaptDx dark adaptation testing is reimbursable under CPT code 92284 (national average $64.08).The device has been validated in numerous clinical studies and is FDA 510(k) cleared.